Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204356 | 0.88 | FGFR1 (0.45) | FGFR1SRCPIK3CAMAPK8MAPK9 | |
| SCHEMBL1553703 | 0.83 | PIK3CA (0.49) | FGFR1SRCPIK3CAMAPK8MAPK9 | |
| SCHEMBL1554045 | 0.81 | PIK3CA (0.35) | FGFR1SRCPIK3CAMAPK8MAPK9 | |
| SCHEMBL1505474 | 0.79 | — | — | |
| SCHEMBL1553842 | 0.76 | ABL1 (0.41) | FGFR1SRCPIK3CAMAPK8MAPK9 | |
| SCHEMBL2137127 | 0.75 | MAPT (0.45) | — | |
| SCHEMBL1553523 | 0.74 | MAPK1 (0.49) | PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL1554037 | 0.73 | MAPT (0.40) | FGFR1SRCABL1 | |
| SCHEMBL1553580 | 0.72 | ABL1 (0.46) | ABL1 | |
| SCHEMBL1553500 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674801-B2 | Alkyl urea substituted pyridines | ASTRAZENECA AB (SE) | 2010-03-09 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132546-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, ABCB11 | FGFR1 3374/4885SRC 2339/4885PIK3CA 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.